M. Pasqua, A. Jafar, A. Kobayati, M. Odabassian, M. Tsoukas, A. Haidar
{"title":"低剂量恩格列净辅助混合闭环胰岛素治疗次优对照成人1型糖尿病:一项随机交叉对照试验","authors":"M. Pasqua, A. Jafar, A. Kobayati, M. Odabassian, M. Tsoukas, A. Haidar","doi":"10.1016/j.jcjd.2023.10.233","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":93918,"journal":{"name":"Canadian journal of diabetes","volume":"93 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"LOW-DOSE EMPAGLIFLOZIN AS ADJUNCT TO HYBRID CLOSED-LOOP INSULIN THERAPY IN SUB-OPTIMALLY CONTROLLED ADULTS WITH TYPE 1 DIABETES: A RANDOMIZED CROSSOVER CONTROLLED TRIAL\",\"authors\":\"M. Pasqua, A. Jafar, A. Kobayati, M. Odabassian, M. Tsoukas, A. Haidar\",\"doi\":\"10.1016/j.jcjd.2023.10.233\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":93918,\"journal\":{\"name\":\"Canadian journal of diabetes\",\"volume\":\"93 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian journal of diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jcjd.2023.10.233\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian journal of diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jcjd.2023.10.233","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
LOW-DOSE EMPAGLIFLOZIN AS ADJUNCT TO HYBRID CLOSED-LOOP INSULIN THERAPY IN SUB-OPTIMALLY CONTROLLED ADULTS WITH TYPE 1 DIABETES: A RANDOMIZED CROSSOVER CONTROLLED TRIAL